Valuation: IXICO plc

Market Cap 18.53M 24.73M 21.72M 20.2M 34.82M 2.38B 35.36M 240M 93.7M 1.17B 92.83M 90.83M 4.05B P/E 2026 *
-6.07x
P/E 2027 * -6.54x
Enterprise Value 8.33M 11.12M 9.77M 9.08M 15.66M 1.07B 15.9M 108M 42.14M 526M 41.74M 40.84M 1.82B EV / Sales 2026 *
1.04x
EV / Sales 2027 * 1.38x
Free-Float
89.22%
Yield 2026 *
-
Yield 2027 * -
3 years 0.07
Extreme 0.07
0.15
5 years 0
Extreme 0.003
1.09
10 years 0
Extreme 0.003
1.47
Manager TitleAgeSince
Chief Executive Officer 53 2024-08-18
Director of Finance/CFO 50 2019-08-20
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 2019-08-20
Director/Board Member 60 2022-01-20
Change 5-day change 1-year change 3-year change Capi.($)
-53.33%-.--% - - 24.73M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -5.13%+0.83%+54.56%+106.44% 27.25B
Weighted average by Cap. +0.47%+0.91%+74.42%+136.27%

Financials

2026 *2027 *
Net sales 8M 10.67M 9.37M 8.72M 15.03M 1.03B 15.26M 104M 40.45M 505M 40.07M 39.2M 1.75B 9M 12.01M 10.55M 9.81M 16.91M 1.16B 17.17M 116M 45.5M 569M 45.08M 44.11M 1.97B
Net income -2.14M -2.86M -2.51M -2.34M -4.03M -275M -4.09M -27.73M -10.83M -135M -10.73M -10.5M -468M -2.8M -3.74M -3.28M -3.05M -5.26M -360M -5.34M -36.25M -14.16M -177M -14.03M -13.73M -612M
Net Debt -10.2M -13.61M -11.95M -11.12M -19.17M -1.31B -19.46M -132M -51.57M -644M -51.09M -49.99M -2.23B -6.1M -8.14M -7.15M -6.65M -11.46M -784M -11.64M -78.94M -30.84M -385M -30.55M -29.89M -1.33B
Logo IXICO plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
79
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0850GBP
Average target price
0.2600GBP
Spread / Average Target
+205.88%

Annual profits - Rate of surprise